Skip to main content

Table 2 AML-related surface molecules as potential targets for CAR therapies

From: Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

Antigen Antibody clone Efficacy in treatment model Effect on normal References
CD47 B6H12
(mouse IgG1)
Treatment initiated 8–12 weeks post transplantation: decrease AML in 3/3 samples (8/8 mice) with clearance of the bone marrow in 3/8 mice No effect on in vitro phagocytosis of CD34+ normal bone marrow progenitors [128]
(Human IgG4)
Completely eradicated human AML in vivo, leading to long-term disease-free survival of patient-derived xenografts Safely administered intravenously at doses by toxicokinetic studies in non-human primates [134]
(human IgG2b)
Effective in killing TIM-3 expressing cell lines by its CDC and ADCC activities;
In vivo xenogeneic transplantation efficiently eradicated AML LSCs
No effect on cord blood or bone marrow engrafted mice [133]
  1. AML acute myeloid leukemia, CDC complement dependent cytotoxicity, ADCC antibody-dependent cell-mediated cytotoxicity, LSC leukemia stem cell